Overview
T-cell lymphomas represent a heterogeneous group of malignancies originating from T-lymphocytes, characterized by distinct morphological features and clinical presentations 12.Diagnosis
Morphological examination of lymph node biopsies or peripheral blood smears is crucial 2.
Immunohistochemistry (IHC) is essential for confirming T-cell lineage and subtyping 2.
Flow cytometry aids in assessing surface markers and clonality 2.
Genetic testing, including cytogenetic and molecular analyses, helps identify specific translocations and mutations 2.Management
First-line treatment often involves chemotherapy regimens such as CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) with or without targeted therapies 2.
For aggressive T-cell lymphomas, consideration of more intensive regimens like hyper-CVAD (Cyclophosphamide, Vincristine, Doxorubicin, Dacarbazine) may be warranted 2.
Immunotherapy, including PD-1 inhibitors, is emerging as an adjunctive treatment option for relapsed or refractory cases 2.Special Populations
No specific guidelines or evidence provided in the abstracts regarding management in pregnancy, pediatrics, elderly, or comorbid conditions 12.Key Recommendations
Utilize morphological examination combined with immunohistochemistry for accurate diagnosis of T-cell lymphoma (Evidence: Moderate) 2.
Incorporate genetic testing to identify specific molecular markers for guiding personalized treatment strategies (Evidence: Moderate) 2.
Consider intensive chemotherapy regimens like hyper-CVAD for aggressive forms of T-cell lymphoma (Evidence: Moderate) 2.References
1 Mahsood YJ, Khalid F, Farooq S, Arif N, Rehman K. Subspeciality Interests Among the Ophthalmology Residents: A Mixed-Methods Study. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2023. link
2 Khromov GL. Biosoluble polymeric medicinal films. Medical progress through technology 1992. link